X-Linked Hypophosphatemia: Improving Clinician Awareness and Management
Credit(s): 0.25 (15 min)
Release Date: Oct 15, 2019
Expiration Date: Nov 21, 2019
Treatment for patients with X-linked hypophosphatemia (XLH) has long been hindered by conventional agents’ monitoring requirements, adverse events, and limited efficacy. Fortunately, in April 2018, an FGF23 blocking antibody became the first FDA-approved agent for XLH. However, because XLH remains a rare disease, clinicians may not be properly equipped to recognize and manage it.
This CME activity, “X-Linked Hypophosphatemia: Improving Clinician Awareness and Management,” will help participants recognize the clinical presentation of XLH, identify the potential short- and long-term complications of XLH, and understand the latest evidence on and role of the recently approved breakthroughs.
Welcome and Introduction
Recognizing XLH and Understanding Its Clinical Manifestations
Managing XLH in Clinical Practice
Q&A Session and Concluding Remarks
This activity is intended for primary care clinicians (e.g. family physicians, pediatricians), the front-line providers likely to first assess and diagnose patients with XLH.
This program is designed to address the following National Academy of Medicine (NAM) competencies: provide patient-centered care and employ evidence-based practice. At the conclusion of this activity, participants should be able to:
Recognize the clinical presentation of XLH
Identify the potential short- and long-term complications of XLH
Discuss the efficacy and safety data for newly approved agents for XLH
Incorporate clinical data and expert recommendations, which include newly approved therapies in management plans for adolescents and adults with XLH
The Potomac Center for Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
CME CREDIT DESIGNATION
The Potomac Center for Medical Education designates this live activity for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the
extent of their participation in the activity.
For information about the accreditation of this program, please email: email@example.com.
ABIM MOC DESIGNATION
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
To receive CME credit and/or MOC points, you MUST complete the onsite evaluation and pass the online post-test at www.rockpointe.com/xlhmoc. For ABIM MOC points, your information will be shared with the ABIM through PCME’s ACCME Program and Activity Reporting System (PARS). Please allow 6-8 weeks for your MOC points to appear on your ABIM records.
ABP PART 2 DESIGNATION
Successful completion of this CME activity, which includes participation in the activity and individual assessment of and feedback to the learner, enables the learner to earn up to 1.0 MOC points in the American Board of Pediatrics’ (ABP) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit learner completion information to ACCME for the purpose of granting ABP MOC credit. To receive CME credit and/or MOC points, you MUST complete the onsite evaluation and pass the online post-test at www.rockpointe.com/xlhmoc. For ABP MOC points, your information will be shared with the ABP through PCME’s ACCME Program and Activity Reporting System (PARS). Please allow 6-8 weeks for your MOC points to appear on your ABP records.
This Live activity, X-Linked Hypophosphatemia: Improving Clinician Awareness and Management, from 08/01/2019 – 12/31/2019, has been reviewed and is acceptable for up to 1.00 Prescribed credit(s) by the American Academy of Family Physicians. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Suzanne Jan De Beur, MD
Associate Professor of Medicine
Johns Hopkins University School of Medicine
Suzanne Jan De Beur, MD is Associate Professor of Medicine at the Johns Hopkins University School of Medicine and Director of the Clinical Research Units of the Johns Hopkins Institute for Clinical and Translational Research. She received her BA and her medical doctorate from Cornell University. She completed the Osler Medical Residency at the Johns Hopkins Hospital and her fellowship in endocrinology and metabolism at the Johns Hopkins University School of Medicine.
As a physician-scientist and practicing endocrinologist, Dr. Jan de Beur’s clinical and research work focuses on understanding rare and metabolic bone diseases at the basic level and translating these observations to the bedside. Specifically, her research interests include understanding the physiology of FGF23 and the molecular basis of disorders of phosphate homeostasis, emerging treatments for rare bone diseases, and the genetic basis of parathyroid hormone resistance syndromes. Dr. Jan de Beur has authored numerous peer-reviewed publications, reviews, and book chapters in high-impact journals, including New England Journal of Medicine, Journal of the American Medical Association, Journal of Clinical Investigation, and The Lancet.
Farzana Perwad, MD
Chief, Division of Nephrology
Director, Pediatric Nephrology Fellowship Program
Director, Scholarship Oversight Committee
University of California San Francisco
Childrens Renal Center
San Francisco, CA
Farzana Perwad, MD is an Associate Professor in the Department of Pediatrics at the University of California San Francisco (UCSF). She is the Division Chief of Pediatric Nephrology at UCSF and her research interests are in the field of bone and mineral disorders related to kidney disease. Specifically, Dr. Perwad’s research focuses on the regulation of vitamin D and phosphorus homeostasis by fibroblast growth factor 23 (FGF23). Her research projects include investigating the pathophysiology of X-linked hypophosphatemia (XLH) in mouse models of XLH, and the molecular mechanisms of action of FGF23 in the kidney.
INSTRUCTIONS FOR PARTICIPANTS AND OBTAINING CME/CE CREDIT
There is no fee for this activity. To receive credit, participants must register, view the live CME activity in its entirety, and then complete the post-test, with a score of 80% or better, and evaluation. The estimated time for completion of this activity is 1 hour. To receive a certificate, participants must demonstrate mastery of the presented material via the post-test. Participants are allowed to take the post-test multiple times. If you will be watching the webinar in a group setting, please note all group participants will need to register individually in order to complete the post-test and evaluation to receive credit. Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Provided by the Potomac Center for Medical Education
This program is supported by an educational grant from Ultragenyx.
Clicking Start Activity indicates that you have reviewed the CME/CE information for this activity
A.C.T. N.O.W.: A Challenge To Neurologists to Open the Window-of-Opportunity for Patients with Early Alzheimer’s Disease
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.